Multidisciplinary Perspectives and the Patient Journey

>> YOUR LINK HERE: ___ http://youtube.com/watch?v=TrXJ1Bkx6VU

Misagh Karimi, MD, Sharyn Lewin, MD, and Diana Czel, APRN, CNP, discuss the patient journey and multidisciplinary perspectives regarding patient management, including information on testing, discussing therapy with patients, and key data from clinical trials. • Learn more: https://bit.ly/3TGxPb0 • In this video, Dr Misagh Karimi, a medical oncologist, Dr Sharyn Lewin, a gynecologic oncologist, and Diana Czel, a nurse practitioner, discuss their perspectives regarding key points related to the patient journey and maintenance therapy with LYNPARZA ± bevacizumab. • LYNPARZA is indicated as maintenance monotherapy for women with BRCAm* advanced ovarian cancer after response to first-line platinum-based chemotherapy or in combination with bevacizumab as maintenance therapy for women with HRD+* advanced ovarian cancer after response to first-line platinum-based chemotherapy. • *Select patients for therapy based on an FDA-approved companion diagnostic • LYNPARZA is associated with serious and potentially fatal adverse events including Myelodysplastic syndrome/acute myeloid leukemia (MDS/AML), pneumonitis, and venous thromboembolism (VTE). Monitor patients for signs and symptoms and discontinue LYNPARZA if MDS/AML or pneumonitis is confirmed. Monitor patients for signs and symptoms of VTE and treat as medically appropriate. LYNPARZA can cause fetal harm. • Please see complete Important Safety Information in the video and at https://www.lynparzahcp.com/ovarian-c... • Please see complete Prescribing Information, including Medication Guide, at https://bit.ly/LYNhcpPI • You may report side effects related to AstraZeneca products by visiting: • https://us-aereporting.astrazeneca.co... • LYNPARZA is a registered trademark of the AstraZeneca group of companies.

#############################

New on site